Introduction {#s1}
============

Mental disorders are extremely common, affecting approximately 18.3% of the U.S. adult population (see 2016 National Survey on Drug Use and Health). The prevalence of many mental disorders, including anxiety and depressive disorders, are higher among women than men (see 2016 National Survey on Drug Use and Health). These gender differences have been attributed, at least partly, to fluctuations of the ovarian hormone estradiol \[see ([@B1])\]. Specifically, an increase in estradiol occurring during female puberty has been associated with increased prevalence of mood disorders \[see ([@B2], [@B3])\]. Additionally, several studies showed that the incidence of depression ([@B4]--[@B6]) and anxiety ([@B7]) increases in women during the menopausal transition, a period that is characterized by robust fluctuations in estrogen levels, before overall levels drop to approximately 10% of estrogen levels during the pre-menopausal period. Although estradiol treatment was shown to alleviate depressive symptoms in women ([@B8], [@B9]), the mechanistic relationship between estrogen and depression remains unclear.

Estradiol exerts its effects through binding to two classical estrogen receptor subtypes, the estrogen receptor alpha (ERα) and beta (ERβ) and the non-classical G-protein coupled estrogen receptor, GPR30 ([@B10]). These receptors have been suggested to play a role in the pathophysiology of mood disorders. Specifically, *Esr1* gene variants, which code for ERα, have been associated with increased risk of developing depression in women ([@B11]--[@B15]). In rats, estradiol, via acting at the ERα, normalized postpartum-induced anxiety- and depressive-like behavior, measured in the elevated-plus maze (EPM) and the forced-swim tests (FST), respectively ([@B16]). Moreover, knockdown of the ERα selectively in the posterior-dorsal amygdala of female mice decreased anxiety-like behavior as demonstrated by the increase time spend in the light compartment of the light/dark box (L/D box) ([@B17]), suggesting a possible role of ERα in regulating anxiety behaviors. Although, the role of ERα has been extensively investigated in women and female animals, its role in male depression and anxiety has received limited attention. However, a genetic association study identified a possible link between *Esr1* polymorphisms and depression in men ([@B18]).

Polymorphisms in *Esr2*, which codes for ERβ have been associated with moderate depressive symptoms in women ([@B18]), whereas there are no studies investigating the role of *Esr2* polymorphisms in male depression. In rodent studies, selective ERβ ligands ([@B19]), as well as estradiol ([@B20]) decrease immobility time in the FST in wild-type, but not *Esr2* knockout female mice. In addition, ERβ, but not ERα, agonists decreased immobility time in the FST in ovariectomized rats ([@B21]), suggesting that activation of ERβ induces antidepressant effects in female rodents. There is a report suggesting antidepressant efficacy of an ERβ agonist in the tail-suspension test in male mice ([@B22]). Administration of the ERβ agonist diarylpropionitrile decreased anxiety-like behaviors in female wild-type mice but not in mice lacking the ERβ receptor gene ([@B23]).

Overall, most of the existing studies that have been published and investigated the role of the estrogen receptors in anxiety and depressive behaviors mainly concentrate on a single sex, as estradiol is considered a "female" hormone. Furthermore, limited studies assessed for the involvement of either ERβ or ERα in behavioral responses to stress. Therefore, in the present study, we sought to understand the role of estrogen receptors in anxiety, as well as in depressive-related behavioral responses following stress in both female and male mice.

Methods {#s2}
=======

Mice
----

*Esr1* and *Esr2* breeding pairs were obtained from Jackson laboratories. Wild-type, heterozygous and homozygous *Esr1* mice were bred in-house by breeding heterozygous males and females. Heterozygous and homozygous *Esr2* mice were bred in-house by breeding heterozygous females and homozygous males. Both *Esr1* and *Esr2* mice were bred on a C57BL/6J background. At the time of behavioral testing, the age of the animals was 8--12 weeks. Mice were grouped-housed and maintained under a 12 h light--dark cycle (lights on at 7:00 a.m.). Water and food was available *ad libitum*. All mice were housed in the same room in individually ventilated cages. All experimental procedures were approved by the University of Maryland Animal Care and Use Committee and were conducted in full accordance with the NIH Guide for the Care and Use of Laboratory Animals. Tail samples were obtained prior to weaning and genotyped by TransnetYX, Inc. (Cordova, TN, USA). The primer sequences are as follows:

*Esr1 genotype: Wild-type*-Forward: TCGGGCATCGCCTACG; Reverse: GGCGACACGCTGTTGAG. *Esr1*-Forward: CATTCTCAGTATTGTTTTGCCAAGTTCT; Reverse: GGCGACACGCTGTTGAG

*Esr2 genotype: Wild-type*-Forward: CCAAGAGGGATGCTCACTTCT: Reverse: CAGACACCGTAATGATACCCAGATG. *Esr2*-Forward: GCCAAGAGGGATGCTCACTTC; Reverse: TCCATCAGAAGCTGACTCTAGAACT.

Behavioral Characterization
---------------------------

All behavioral experiments were performed during the light phase of the light/dark cycle between 10:00 a.m. and 3:00 p.m. The order of testing within animals ([Figure 1A](#F1){ref-type="fig"}) was determined by the degree of stressfulness of each test with the least stressful conducted first and the most potentially distressing test last ([@B24]--[@B26]). The numbers of animals used for the open-field test, light/dark box, elevated-plus maze, novel-object recognition, forced-swim test, learned helplessness, shock sensitivity and sucrose preference are as follows---*Esr1*^+/+^, *Esr1*^+/−^, *Esr1*^−/−^ Females: *n* = 12, 20, 11; Males: *n* = 8, 12, 9 and *Esr2*^+/−^, *Esr2*^−/−^ Females: *n* = 9, 8; Males: *n* = 13, 11. The numbers of animals used for the pre-pulse inhibition and amphetamine-induced hyperlocomotion are as follows---*Esr1*^+/+^, *Esr1*^+/−^, *Esr1*^−/−^ Females: *n* = 11, 11, 10; Males: *n* = 10, 10, 8 and *Esr2*^+/−^, *Esr2*^−/−^ Females: *n* = 11, 9; Males: *n* = 7, 8.

![Timeline of behavioral experiments. Timeline of **(A)** the sucrose preference, open-field test, novel-object recognition, light/dark box, elevated-plus maze, forced-swim test, learned helplessness and shock sensitivity. Timeline of **(B)** pre-pulse inhibition and amphetamine-induced hyperlocomotion.](fpsyt-10-00081-g0001){#F1}

### Open-Field Test (OFT)

The OFT was performed under 300 Lux white lighting. Mice were individually placed into open-field arenas (100 × 100 × 38 cm; San Diego Instruments, San Diego, CA) for a 10-min period. The sessions were recorded using an overhead, digital video-camera. Distanced traveled and time spent in the center of the arena was analyzed using TopScan v2.0 (CleverSys, Inc., Reston VA).

### Light/Dark Box (L/D box)

The L/D box was used as previously described ([@B26]), with minor modifications. Briefly, mice were placed in the illuminated compartment of the L/D box (35 × 35 cm), facing the wall opposite to the dark compartment, and allowed to explore the whole apparatus for 5 min. The sessions were recorded using a video-camera and the time spent in the illuminated and dark compartment was scored using TopScan v2.0 (CleverSys, Inc., Reston VA).

### Elevated-Plus Maze (EPM)

The EPM was carried in dim white lighting conditions (\~5 lux). The apparatus consisted of 2 closed arms and 2 open arms (39 × 5 cm each) and was elevated 50 cm above the floor (Stoelting, Woodale, IL). The experiment was carried out as previously described ([@B27]). The time spent in the open and closed arms of the EPM during the 5-min test was recorded by an over-head digital video-camera and scored using TopScan v2.0 (CleverSys, Inc., Reston VA). Amount of time spent in the open arms was used as the primary outcome for the anxiety behavioral assessment.

### Novel-Object Recognition (NOR)

Short-term recognition memory was assessed using the novel object recognition task protocol, as previously described ([@B28], [@B29]). The NOR was carried in dim white lighting conditions (\~10--15 lux). The apparatus and objects used here has been previously described by Zanos et al. ([@B28]). The test was conducted over two days. On the first day, the habituation phase, the animals were allowed to explore an empty novel object recognition apparatus (40 × 9 × 23 cm) for 30 min and then returned to their home cages. On the second day, the mice were re-introduced into the same apparatus, but this time containing two identical objects fixed on the floor, which they were allowed to explore for 30 min. After this familiarization phase, mice were immediately returned to their home-cages for 30 min. The mice were then placed back into the novel object recognition apparatus, in which one of the "familiar" objects was replaced by a "novel" object (retention phase) for 4 min. All three phases of the novel object recognition test were recorded via an overhead video-camera and analyzed using TopScan v2.0 automated scoring software (CleverSys, Inc., Reston VA). The time spent interacting with the familiar and novel objects during the retention phase was measured. A discrimination ratio was calculated by dividing the time of interaction with the novel object by the total time of interaction with both objects during the retention phase.

### Forced-Swim Test (FST)

The FST was performed in normal white light conditions (\~300 lux) and was performed as previously described ([@B30]). Briefly, mice were subjected to a 6-min swim session in clear Plexiglas cylinders (30-cm height × 20-cm diameter) filled with 15 cm of water (23 ± 1°C). Sessions were recorded using a digital video camera. Immobility time, defined as passive floating with no additional activity other than that necessary to keep the animal\'s head above water, was scored for the last 4 min of the 6-min test by a trained experimenter blind to the genotypes.

### Learned Helplessness

The learned helplessness paradigm was performed in accordance with Dao et al. ([@B31]) and was separated in two phases: training and test. On Day 1 mice received inescapable shock training (0.3 mA, 2 s shock duration 120 trials, inter-trial interval 15 s) in one compartment of the two-compartment Coulbourn Mouse Shuttle Cage (Coulbourn Instruments, Whitehall, PA). On day 2, learned helplessness test consisted of 45 escapable shock trials (0.3 mA, duration of open door: 15 s). The average inter-trial interval was 20 s. In trials 1--5, the gate opened concomitantly with the shock initiation and stayed open for the duration of the shock. In trials 6--45, the gate with a 3 s delay after initiation of the shock. In all trials, shock was terminated if mice passed through the gate to the other compartment. Number of escape failures and escape latency was automatically measured by GraphicState 3.01 (Coulbourn Instruments, Whitehall, PA).

### Shock Sensitivity Test

Mice were tested for their sensitivity to shock as previously described with minor modifications ([@B32]). Briefly, mice were subjected to increment shock intensities (0.02--0.50 mA; 0.02 mA increments from 0.02 to 0.2 mA and 0.5 mA increments from 0.2 to 0.5 mA) and testing for their flinch response. The increments occurred every 30 s and the shock delivery were automatically controlled by GraphicState 3.01 (Coulbourn Instruments, Whitehall, PA). Scoring was performed live by an experienced experimenter blind to the genotypes.

### Sucrose Preference Test

For assessing the baseline sucrose preference, mice were singly housed for 72 h and presented with two identical bottles containing either tap water or 1% sucrose solution. After baseline sucrose measurement, mice were re-group housed. Following the learned helplessness testing, similar to the baseline measurements, mice were singly housed for 72 h and presented with two identical bottles containing either tap water or 1% sucrose solution. The location of the sucrose and tap water bottle was changed every day to avoid the development of side preference.

### Pre-pulse Inhibition (PPI)

The pre-pulse inhibition (PPI) paradigm was performed as previously described ([@B33]), with minor modifications. Mice were individually tested in acoustic startle boxes (SR-LAB; San Diego Instruments, San Diego, CA). The animals were placed in the startle chamber for a 30-min habituation period. The experiment started with a further 5-min adaptation period during which the mice were exposed to a constant background noise (67 db), followed by five initial startle stimuli (120 db, 40-ms duration each). Subsequently, animals were exposed to five different trial types: pulse alone trials (120 db, 40-ms duration), three prepulse trials of 76, 81, and 86 db of white noise bursts (20-ms duration) preceding a 120-db pulse by 100 ms, and background (67 db) no-stimuli trials. Each of these trials was randomly presented five times. The percentage PPI was calculated using the following formula: \[(magnitude on pulse alone trial---magnitude on prepulse + pulse trial)/magnitude on pulse alone trial\] × 100.

### Amphetamine-Induced Hyperlocomotion

The amphetamine-induced hyperlocomotion experiment was performed under white lighting conditions of \~80 lux. Mice were placed into the open-field arenas (50 × 50 × 38 cm; San Diego Instruments) for a 30-min habituation period, as described in the OFT protocol above. Following the habituation period, the locomotion response to a saline injection (5 ml/kg, i.p.) was assessed for 30-min. After that, mice were administered *d-*amphetamine (2 mg/kg, i.p.; Sigma-Aldrich, St. Louis, MO) and placed back to the arena for 60-min to assess their locomotion response. Distanced traveled and time spent in the center of the arena was analyzed using TopScan v2.0 (CleverSys, Inc., Reston VA).

All the behavioral assessments were performed by an experimenter blind to the genotype of animals. The OFT, novel object recognition, L/D box, EPM, FST, learned helplessness, sucrose preference and shock sensitivity were performed on the same animals starting from the least to the most stressful test (for timeline see [Figure 1A](#F1){ref-type="fig"}). There was a 7-day gap period between the FST and learned helplessness and a 7-day gap between sucrose preference post-stress and shock sensitivity, when mice remained undisturbed in their home cages. The PPI and amphetamine-induced hyperlocomotion was performed on the same animals with at least a 7-day gap between these tests (for timeline see [Figure 1B](#F1){ref-type="fig"}).

Statistical Analysis
--------------------

The OFT, L/D box, EPM, novel object recognition, FST, and acoustic startle as well as, the total escape failures in the learned helplessness test with the wild-type, heterozygous and homozygous *Esr1* mice were analyzed using one-way ANOVA. The OFT, L/D box, EPM, novel object recognition, FST, and acoustic startle as well as, the total escape failures in the learned helplessness test with the heterozygous and homozygous *Esr2* mice were analyzed with an unpaired Student\'s *t*-test. The average escape latency, escape failures, sucrose preference, pre-pulse inhibition and amphetamine-induced hyperlocomotion for both *Esr1* and *Esr2* were analyzed with a repeated measure two-way ANOVA. Datasets that fail to pass normality test as tested by Shapiro-Wilk test, were analyzed by Kruskal-Wallis and Mann-Whitney test. Fisher\'s exact test was used as an additional analysis for % pre-pulse inhibition to test whether the proportion of mice decreased their PPI was significantly different between genotypes. The male and female mice experiments were performed in separate cohorts, and thus are not combined on the same graphs and statistical analyses. Holm-Sidak *post-hoc* test was performed when a significant interaction effect was observed in the ANOVAs. Statistical significance was set at *p* \< 0.05. All analyses were performed using GraphPad Prism *v* 6.01. All values are expressed as mean ± SEM. Statistical details are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Details of statistical analyses.

  --------------------------------------------------------- ------------------------ ------------- ------------------------- -------------- ------------------------- --------------
  **OVERALL EFFECTS FOR [FIGURE 2](#F2){ref-type="fig"}**                                                                                                             
  **Males**                                                                                                                                                           
  Distance traveled                                         *F*~(2,\ 26)~ = 1.703    *P =* 0.202                                                                      
  Time in center                                            *F*~(2,\ 26)~ = 0.308    *P =* 0.738                                                                      
  Light/Dark Box                                            *F*~(2,\ 24)~ = 0.991    *P =* 0.386                                                                      
  Elevated-plus maze                                        *F*~(2,\ 25)~ = 1.697    *P =* 0.204                                                                      
  Novel-object recognition                                  *F*~(2,\ 24)~ = 0.352    *P =* 0.707                                                                      
  Forced -swim test                                         *F*~(2,\ 26)~ = 0.810    *P =* 0.456                                                                      
                                                            **Genotype**                           **Intensity**                            **Interaction**           
  Pre-pulse inhibition                                      *F*~(2,\ 25)~ = 0.124    *P =* 0.884   *F*~(2,\ 50)~ = 1.970     *P =* 0.150    *F*~(4,\ 50)~ = 0.7864    *P =* 0.540
  Amphetamine-induced hyperlocomotion                       **Genotype**                           **Time**                                 **Interaction**           
  Timeline                                                  *F*~(2,\ 29)~ = 6.408    *P* = 0.005   *F*~(23,\ 667)~ = 78.3    *P* \< 0.001   *F*~(46,\ 667)~ = 2.866   *P* \< 0.001
  Total distance traveled                                   *F*~(2,\ 29)~ = 6.408    *P* = 0.005   *F*~(2,\ 58)~ = 210.8     *P* \< 0.001   *F*~(4,\ 58)~ = 5.628     *P* \< 0.001
  **Females**                                                                                                                                                         
  Distance traveled                                         *F*~(2,\ 40)~ = 3.047    *P =* 0.059                                                                      
  Time in center                                            *F*~(2,\ 40)~ = 0.385    *P =* 0.683                                                                      
  Light/Dark Box                                            *F*~(2,\ 40)~ = 0.057    *P =* 0.945                                                                      
  Elevated-plus maze                                        *H* = 0.696, *Df* = 2    *P =* 0.706                                                                      
  Novel-object recognition                                  *F*~(2,\ 39)~ = 0.201    *P =* 0.819                                                                      
  Forced -swim test                                         *H* = 1.253, *Df* = 2    *P =* 0.535                                                                      
  Pre-pulse inhibition                                      *H* = 6.646, *Df* = 8    *P =* 0.575                                                                      
  Amphetamine-induced hyperlocomotion                       **Genotype**                           **Time**                                 **Interaction**           
  Timeline                                                  *F*~(2,\ 29)~ = 1.362    *P* = 0.272   *F*~(23,\ 667)~ = 66.1    *P* \< 0.001   *F*~(46,\ 667)~ = 2.552   *P* \< 0.001
  Total distance traveled                                   *F*~(2,\ 29)~ = 1.362    *P* = 0.272   *F*~(2,\ 58)~ = 116.8     *P* \< 0.001   *F*~(4,\ 58)~ = 2.259     *P* = 0.074
  **OVERALL EFFECTS FOR [FIGURE 3](#F3){ref-type="fig"}**                                                                                                             
  **Males**                                                 **Genotype**                           **Time**                                 **Interaction**           
  Escape latency                                            *F*~(2,\ 26)~ = 0.698    *P* = 0.507   *F*~(8,\ 208)~ = 1.246    *P* = 0.274    *F*~(16,\ 208)~ = 0.211   *P* = 0.999
  Escape failures                                           *F*~(2,\ 26)~ = 0.774    *P* = 0.472   *F*~(8,\ 208)~ = 3.763    *P* = 0.000    *F*~(16,\ 208)~ = 0.186   *P* = 0.999
  Total escape failures                                     *F*~(2,\ 26)~ = 0.774    *P* = 0.472                                                                      
  Sucrose preference                                        *H* = 0.213, *Df* = 2    *P* = 0.213                                                                      
  **Females**                                                                                                                                                         
  Escape latency                                            *H* = 39.41, *Df* = 26   *P* = 0.046                                                                      
  Escape failures                                           *H* = 40.06, *Df* = 26   *P* = 0.039                                                                      
  Total escape failures                                     *H* = 7.167, *Df* = 2    *P* = 0.028                                                                      
                                                            **Genotype**                           **Time**                                 **Interaction**           
  Sucrose preference                                        *F*~(2,\ 26)~ = 0.869    *P* = 0.431   *F*~(1,\ 26)~ = 6.488     *P* = 0.017    *F*~(2,\ 26)~ = 1.357     *P* = 0.275
  **OVERALL EFFECTS FOR [FIGURE 4](#F4){ref-type="fig"}**                                                                                                             
  **Males**                                                                                                                                                           
  Distance traveled                                         *t*~(22)~ = 0.170        *P* = 0.867                                                                      
  Time in center                                            *t*~(22)~ = 0.273        *P* = 0.787                                                                      
  Light/Dark Box                                            *t*~(22)~ = 0.960        *P* = 0.347                                                                      
  Elevated-plus maze                                        *t*~(22)~ = 0.433        *P* = 0.669                                                                      
  Novel-object recognition                                  *t*~(22)~ = 0.145        *P* = 0.886                                                                      
  Forced -swim test                                         *t*~(22)~ = 0.510        *P* = 0.615                                                                      
                                                            **Genotype**                           **Intensity**                            **Interaction**           
  Pre-pulse inhibition                                      *F*~(1,\ 12)~ = 1.329    *P* = 0.271   *F*~(2,\ 24)~ = 19.58     *P* \< 0.001   *F*~(2,\ 24)~ = 1.083     *P* = 0.355
  Amphetamine-induced hyperlocomotion                       **Genotype**                           **Time**                                 **Interaction**           
  Timeline                                                  *F*~(1,\ 13)~ = 0.035    *P* = 0.854   *F*~(23,\ 299)~ = 57.2    *P* \< 0.001   *F*~(23,\ 299)~ = 0.444   *P* = 0.989
  Total distance traveled                                   *F*~(1,\ 13)~ = 0.035    *P* = 0.854   *F*~(2,\ 26)~ = 111.7     *P* \< 0.001   *F*~(2,\ 26)~ = 0.0252    *P* = 0.975
  **Females**                                                                                                                                                         
  Distance traveled                                         *t*~(15)~ = 0.619        *P* = 0.545                                                                      
  Time in center                                            *t*~(15)~ = 1.216        *P* = 0.243                                                                      
  Light/Dark Box                                            *t*~(15)~ = 0.536        *P* = 0.580                                                                      
  Elevated-plus maze                                        *U* = 27.0               *P* = 0.416                                                                      
  Novel-object recognition                                  *t*~(15)~ = 0.077        *P* = 0.940                                                                      
  Forced -swim test                                         *t*~(15)~ = 0.131        *P* = 0.898                                                                      
                                                            **Genotype**                           **Intensity**                            **Interaction**           
  Pre-pulse inhibition                                      *F*~(1,\ 17)~ = 6.373    *P* = 0.022   *F*~(2,\ 34)~ = 5.197     *P* = 0.011    *F*~(2,\ 34)~ = 2.892     *P* = 0.069
  Amphetamine-induced hyperlocomotion                       **Genotype**                           **Time**                                 **Interaction**           
  Timeline                                                  *F*~(1,\ 13)~ = 2.037    *P* = 0.177   *F*~(23,\ 299)~ = 149.8   *P* \< 0.001   *F*~(23,\ 299)~ = 2.367   *P* \< 0.001
  Total distance traveled                                   *F*~(1,\ 13)~ = 2.037    *P* = 0.177   *F*~(2,\ 26)~ = 659.3     *P* \< 0.001   *F*~(2,\ 26)~ = 4.787     *P* = 0.017
  **OVERALL EFFECTS FOR [FIGURE 5](#F5){ref-type="fig"}**                                                                                                             
  **Males**                                                                                                                                                           
  Escape latency                                            *H* = 27.59, *Df* = 17   *P* = 0.050                                                                      
  Escape failures                                           *H* = 28.30, *Df* = 17   *P* = 0.042                                                                      
  Total escape failures                                     *U* = 51.50              *P* = 0.254                                                                      
                                                            **Genotype**                           **Time**                                 **Interaction**           
  Sucrose preference                                        *F*~(1,\ 22)~ = 6.001    *P* = 0.023   *F*~(1,\ 22)~ = 5.644     *P* = 0.027    *F*~(1,\ 22)~ = 17.63     *P* = 0.000
  **Females**                                                                                                                                                         
  Escape latency                                            *F*~(1,\ 14)~ = 3.489    *P* = 0.083   *F*~(8,\ 112)~ = 1.674    *P* = 0.113    *F*~(8,\ 112)~ = 2.116    *P* = 0.040
  Escape failures                                           *F*~(1,\ 14)~ = 0.947    *P* = 0.347   *F*~(8,\ 112)~ = 3.068    *P* = 0.004    *F*~(8,\ 112)~ = 1.219    *P* = 0.294
  Total escape failures                                     *t*~(14)~ = 2.274        *P* = 0.039                                                                      
  Sucrose preference                                        *H* = 6.863, *Df* = 3    *P* = 0.076                                                                      
  --------------------------------------------------------- ------------------------ ------------- ------------------------- -------------- ------------------------- --------------

Results {#s3}
=======

Effects of *Esr1* and *Esr2* Genes on Anxiety-Related Behaviors in Male and Female Mice
---------------------------------------------------------------------------------------

### Open-Field Test

We first assessed OFT behavior in male and female heterozygous (*Esr1*^+/−^) and homozygous (*Esr1*^−/−^) *Esr1* mice, as well as their littermate wild-type controls (*Esr1*^+/+^). No difference was observed in the total distance traveled between the groups in both male ([Figure 2A](#F2){ref-type="fig"}) and female mice ([Figure 2K](#F2){ref-type="fig"}). Similarly, no difference was observed in the time-spent in the center of the open field arena in male ([Figure 2B](#F2){ref-type="fig"}) and female mice ([Figure 2L](#F2){ref-type="fig"}).

![Baseline behavioral characterization of male and female *Esr1*^+/+^, *Esr1*^+/−^ and *Esr1*^−/−^ mice. In male mice, no effect of genotype was observed between in **(A,B)** the open-field test, **(C)** light/dark box, **(D)** elevated-plus maze, **(E)** novel-object recognition, **(F)** forced-swim test, **(G)** pre-pulse inhibition and **(H)** contingency representation of pre-pulse inhibition. **(I,J)** An attenuated amphetamine response was observed in the male *Esr1*^−/−^ mice compared with *Esr1*^+/+^ and *Esr1*^+/−^ mice. In female mice, no genotype difference was observed in **(K,L)** the open-field test, **(M)** light/dark box, **(N)** elevated-plus maze, **(O)** novel-object recognition, **(P)** forced-swim test, **(Q)** pre-pulse inhibition and **(R)** contingency representation of pre-pulse inhibition. **(S,T)** An enhanced amphetamine response was observed in the male *Esr1*^−/−^ mice compared with *Esr1*^+/+^ and *Esr1*^+/−^ mice. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001; *n* = 8, 12, 9 for **(A--F)**, *n* = 10, 10, 8 for **(G--J)**, *n* = 12, 20, 11 for **(K--P)**, *n* = 11, 11, 10 for **(Q--T)**.](fpsyt-10-00081-g0002){#F2}

![Effects of stress in male and female *Esr1*^+/+^, *Esr1*^+/−^ and *Esr1*^−/−^ mice. In male mice no effect of genotype was observed following inescapable shock training in **(A)** escape latency, **(B,C)** escape failures and **(D)** sucrose preference. In female mice no effect of genotype was observed following inescapable schok training in **(E)** escape latency **(F,G)** escape failures and **(H)** sucrose preference. *n* = 8, 12, 9 for **(A--D)**, *n* = 12, 20, 11 for **(E--H)**.](fpsyt-10-00081-g0003){#F3}

Moreover, OFT behavior was assessed in male and female heterozygous (*Esr2*^+/−^) and homozygous (*Esr2*^−/−^) *Esr2* mice. No difference was observed in the total distance traveled between the genotype groups in both male ([Figure 4A](#F4){ref-type="fig"}) and female mice ([Figure 4K](#F4){ref-type="fig"}). Similarly, no difference was observed in the time-spent in the center of the open field arena in male ([Figure 4B](#F4){ref-type="fig"}) and female mice ([Figure 4L](#F4){ref-type="fig"}).

![Baseline behavioral characterization of male and female *Esr2*^+/−^ and *Esr2*^−/−^ mice. No difference was observed between the different genotypes in male mice in **(A,B)** the open-field test, **(C)** light/dark box, **(D)** elevated-plus maze, **(E)** novel-object recognition, **(F)** forced-swim test, **(G)** pre-pulse inhibition, **(H)** contingency representation of pre-pulse inhibition and **(I,J)** amphetamine-induced hyperlocomotion. No difference was observed between the different genotypes in female mice in **(K,L)** the open-field test, **(M)** light/dark box, **(N)** elevated-plus maze, **(O)** novel-object recognition and **(P)** forced-swim test. **(Q)** Female *Esr2*^−/−^ mice showed higher pre-pulse inhibition compared with *Esr2*^+/−^ mice. **(R)** No difference was observed in contingency representation of pre-pulse inhibition. **(S,T)** An enhanced amphetamine response was observed in the male *Esr2*^−/−^ mice compared with *Esr2*^+/−^ mice. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01; *n* = 13, 11 for **(A--F)**, *n* = 7, 8 for **(G--J)**, *n* = 9, 8 for **(K--P)**, *n* = 11, 9 for **(Q--T)**.](fpsyt-10-00081-g0004){#F4}

### Light/Dark Box

We measured the time that mice choose to spend in the brightly illuminated area of the L/D box. No effect of *Esr1* knocked-down (neither *Esr1*^+/−^ or *Esr1*^−/−^) was observed in the in male ([Figure 2C](#F2){ref-type="fig"}) or female ([Figure 2M](#F2){ref-type="fig"}) mice compared with their wild-type littermates.

In addition, both male ([Figure 4C](#F4){ref-type="fig"}) and female ([Figure 4M](#F4){ref-type="fig"}) *Esr2*^−/−^ and *Esr2*^+/−^ mice spent similar time in the illuminated area of the L/D box.

### Elevated-Plus Maze

We measured the time mice choose to spend in the open arms of the EPM. No difference was observed between the different genotypes (*Esr1*^+/+^, *Esr1*^+/−^, or *Esr1*^−/−^) in male ([Figure 2D](#F2){ref-type="fig"}) and female ([Figure 2N](#F2){ref-type="fig"}) mice.

Also, no difference was observed between the different genotypes in male ([Figure 4D](#F4){ref-type="fig"}) and female ([Figure 4N](#F4){ref-type="fig"}) *Esr2* mice.

Effects of *Esr1* and *Esr2* Deletion on Novel Object Memory in Male and Female Mice
------------------------------------------------------------------------------------

Short-term recognition memory was assessed using the novel object recognition test. Neither male ([Figure 2E](#F2){ref-type="fig"}) or female ([Figure 2O](#F2){ref-type="fig"}) *Esr1*^−/−^ mice manifest object recognition impairment, since there was no difference in the novel object recognition discrimination ratio compared with the wild-type controls.

Moreover, both male ([Figure 4E](#F4){ref-type="fig"}) and female ([Figure 4O](#F4){ref-type="fig"}) *Esr2* mice did not show any genotype dependent object recognition impairment as assessed with a novel object recognition discrimination ratio.

Effect of *Esr1* and *Esr2* Deletion on Sensorimotor Gating in Male and Female Mice
-----------------------------------------------------------------------------------

Sensorimotor gating deficits were assessed using the PPI paradigm. No statistically significant difference was observed in either male ([Figures 2G,H](#F2){ref-type="fig"}) or female ([Figures 2Q,R](#F2){ref-type="fig"}) *Esr1*^−/−^ mice in the % PPI. However, Fisher\'s exact test revealed a near significant difference between female *Esr1*^+/+^ and *Esr1*^−/−^ ([Figure 2R](#F2){ref-type="fig"}). No difference was observed between the genotypes in the startle amplitude (Male mice-*Esr1*^+/+^: 250.8 ± 53.14, *Esr1*^+/−^: 235.9 ± 74.03, *Esr1*^−/−^: 270.5 ± 59.86; Female mice-*Esr1*^+/+^: 156.0 ± 30.29, *Esr1*^+/−^: 148.9 ± 32.97, *Esr1*^−/−^: 265.2 ± 63.61).

No difference was observed in male *Esr2*^−/−^ mice in the % PPI ([Figures 4G,H](#F4){ref-type="fig"}) and in the startle amplitude (*Esr2*^+/−^: 231.1 ± 36.26, *Esr2*^−/−^: 205.3 ± 26.94) compared with their littermate controls. However, an increase in the % PPI was observed in female *Esr2*^−/−^ compared with *Esr2*^+/−^ mice ([Figure 4Q](#F4){ref-type="fig"}). No difference was observed in the contingency analysis ([Figure 4R](#F4){ref-type="fig"}) and startle response (*Esr2*^+/−^: 197.3 ± 30.16, *Esr2*^−/−^: 166.6 ± 34.57).

Effect of *Esr1* and *Esr2* Deletion on *d*-Amphetamine-Induced Hyperlocomotion in Male and Female Mice
-------------------------------------------------------------------------------------------------------

An increase in locomotor activity was observed in both male \[*F*~(46,\ 667)~ = 2.866, *p* \< 0.001; [Figure 2I](#F2){ref-type="fig"}- *F*~(4,\ 58)~ = 5.628, *p* \< 0.001; [Figure 2J](#F2){ref-type="fig"}\] and female mice \[*F*~(46,\ 667)~ = 2.552, *p* \< 0.001; [Figure 2S](#F2){ref-type="fig"}- *F*~(4,\ 58)~ = 2.259, *p* = 0.074; [Figure 2T](#F2){ref-type="fig"}\] from all the genotypes. However, male *Esr1*^−/−^ mice showed a lower response to *d*-amphetamine as indicated by the lower distance traveled compared with *Esr1*^+/+^ (*p* \< 0.001) and *Esr1*^+/−^ (*p* \< 0.01) mice ([Figures 2I,J](#F2){ref-type="fig"}). In contrast, female *Esr1*^−/−^ mice had a greater response to the *d*-amphetamine compared with *Esr1*^+/+^ and *Esr1*^+/−^ mice ([Figures 2S,T](#F2){ref-type="fig"}).

Following administration of *d*-amphetamine, an increase in locomotor activity was observed in both male ([Figures 4I,J](#F4){ref-type="fig"}) and female mice ([Figures 4S,T](#F4){ref-type="fig"}) from all the genotypes. No difference was observed in the *d*-amphetamine-induced hyperlocomotion between male *Esr2*^+/−^ and *Esr2*^−/−^ mice ([Figures 4I,J](#F4){ref-type="fig"}). In contrast, female *Esr2*^−/−^ mice had a greater locomotor response to *d*-amphetamine as shown by the higher distance traveled compared with *Esr2*^+/−^ mice \[*F*~(23,\ 299)~ = 2.367, *p* \< 0.001; [Figure 4S](#F4){ref-type="fig"}- *F*~(2,\ 26)~ = 4.787, *p* = 0.017; [Figure 4T](#F4){ref-type="fig"}\].

Effects of *Esr1* and *Esr2* Deletion on Behavioral Despair and Anhedonia in Male and Female Mice
-------------------------------------------------------------------------------------------------

### Forced-Swim Test

Behavioral despair was assessed using the FST in male and female *Esr1*^+/−^ and *Esr1*^−/−^ mice, as well as their littermate wild-type controls. Under baseline conditions, no effect of the deletion of *Esr1* was observed in the FST in either male ([Figure 2E](#F2){ref-type="fig"}) or female mice ([Figure 2P](#F2){ref-type="fig"}).

No difference was also observed between *Esr2*^+/−^ and *Esr2*^−/−^ in the immobility time in male ([Figure 4F](#F4){ref-type="fig"}) and female mice ([Figure 4P](#F4){ref-type="fig"}).

### Learned Helplessness

Development of helpless behavior was tested following inescapable shock. No difference in the escape latency ([Figure 3A](#F3){ref-type="fig"}), and escape failures ([Figures 3B,C](#F3){ref-type="fig"}) was identified between male *Esr1*^+/−^, or *Esr1*^−/−^ mice compared with their littermate wild-type controls. In agreement, there was no difference in escape latency ([Figure 3E](#F3){ref-type="fig"}) and escape failures ([Figures 3F,G](#F3){ref-type="fig"}) between *Esr1*^−/−^, *Esr1*^+/−^ and *Esr1*^+/+^ mice. The learned helplessness response was not affected by differences in shock perception since no differences were observed in the flinch response in the shock sensitivity test by either male (*Esr1*^+/+^: 0.045 ± 0.005, *Esr1*^+/−^: 0.037 ± 0.028, *Esr1*^−/−^: 0.055 ± 0.027) or female (*Esr1*^+/+^: 0.047 ± 0.006, *Esr1*^+/−^: 0.054 ± 0.026, *Esr1*^−/−^: 0.038 ± 0.023) mice.

No difference in the escape latency ([Figure 5A](#F5){ref-type="fig"}), and escape failures ([Figures 5B,C](#F5){ref-type="fig"}) between the male *Esr2*^+/−^ and *Esr2*^−/−^; while female *Esr2*^−/−^ mice had lower escape latency \[*F*~(8,\ 112)~ = 2.116, *p* = 0.04; [Figure 5E](#F5){ref-type="fig"}\] and lower total escape failures \[*t*~(14)~ = 2.274, *p* = 0.039; [Figure 5G](#F5){ref-type="fig"}\] compared with *Esr2*^+/−^ mice. Although, there was a statistical significance difference in the average escape latency and total escape failures, the breakdown of escape failures does not reach statistical significance ([Figure 5F](#F5){ref-type="fig"}). The learned helplessness response was not affected by any differences in shock perception since no differences were observed in the flinch response in the shock sensitivity test by both male (*Esr2*^+/−^: 0.057 ± 0.007, *Esr2*^−/−^: 0.062 ± 0.007) and female (*Esr2*^+/−^: 0.091 ± 0.005, *Esr2*^−/−^: 0.090 ± 0.007) mice.

![Effects of stress in male and female *Esr2*^+/−^ and *Esr2*^−/−^ mice. No difference was observed between the different genotypes following inescapable shock training in male mice in the **(A)** escape latency and **(B,C)** escape failures. **(D)** Male *Esr2*^−/−^ mice decreased their sucrose preference following stress compared with their baseline and *Esr2*^+/−^ mice. Female *Esr2*^−/−^ mice demonstrated decreased **(E)** escape latency. Although no statistically significant difference was observed in the **(F)** escape failures timeline, **(G)** female *Esr2*^−/−^ mice had lower total escape failures compared with *Esr2*^+/−^ mice. **(H)** No difference was observed in the pre- and post-stress sucrose preference. ^\*^*p* \< 0.05, ^\*\*\*^*p* \< 0.001; *n* = 13, 11 for **(A--D)**, *n* = 9, 8 for **(E--H)**.](fpsyt-10-00081-g0005){#F5}

### Sucrose Preference

The development of anhedonia was tested at baseline (stress-naïve) conditions and following footshock stress (as described in the learned helplessness experiment) in male and female *Esr1*^+/−^ and *Esr1*^−/−^ mice, as well as wild-type control mice. No differences were observed between the different genotypes at baseline sucrose preference following stress in either male ([Figure 3D](#F3){ref-type="fig"}) or female mice ([Figure 3H](#F3){ref-type="fig"}).

In addition, the development of anhedonia was tested at baseline and following the learned helplessness procedure in male and female *Esr2*^+/−^ and *Esr2*^−/−^ mice. Although no difference was observed in sucrose preference prior to learned helplessness, following stress, male *Esr2*^−/−^ mice decreased their sucrose preference compared with controls as well as compared with their pre-stress sucrose preference \[*F*~(1,\ 22)~ = 17.63, *p* \< 0.001; [Figure 5D](#F5){ref-type="fig"}\]. No difference was observed in female *Esr2*^−/−^ and *Esr2*^+/−^ mice was observed both before and after stress ([Figure 5H](#F5){ref-type="fig"}).

Discussion {#s4}
==========

In the present study, we demonstrate that the lack of ERα and ERβ are differentially involved in the development of helplessness and anhedonia in male and female mice following stress. To our knowledge, this is the first study to investigate the effects ERα and ERβ using knockout mice in the development of helplessness, i.e., increase in escape failures following inescapable shock training, as well as the development of anhedonia following stress in both male and female mice. We demonstrate that female *Esr2*^−/−^ mice manifested significantly lower escape failures in the learned helplessness test, as well as an overall higher sucrose preference prior and after the learned helplessness stress compared with the heterozygous controls suggesting that deletion of *Esr2* gene might be beneficial against the development of maladaptive behaviors following stress. Our finding is not in line with previous findings that administration of ERβ agonists in ovariectomized female rats decrease immobility time in the FST ([@B21], [@B34]). The different approaches used to investigate the role of ERβ in responses to stress between the aforementioned and present study might account for these differences. For example, here we investigated the development of helplessness following the exposure of mice to stress (inescapable shock), whereas the previously published reports used the FST in stress-naïve rats as a measure of antidepressant efficacy of ERβ agonists. Moreover, our use of intact mice vs. the use of ovariectomized rats in this earlier study might also contribute to these differences.

While we demonstrate that deletion of *Esr2* gene in female mice has a protective effect against the development of helplessness, this is not the case in male *Esr2*^−/−^ mice, which had similar escape failures compared to the *Esr2*^+/−^ mice. However, we observed a decrease in sucrose preference following inescapable shock stress in male *Esr2*^−/−^ compared with *Esr2*^+/−^ control mice, suggesting that *Esr2*^−/−^ male mice are more susceptible to stress-induced anhedonia. To our knowledge this is the first study to demonstrate a role of *Esr2* gene in male mice in the development of stress-induced anhedonia, a core symptom of depression in humans, and further investigation is warranted to identify the specific role of this receptor in male depression.

In contrast with the effects of *Esr2* deletion, following inescapable shock, we did not observe any statistically significant differences in either male or female *Esr1*^−/−^ mice compared with either wild-type and heterozygous littermates. Moreover, neither male nor female *Esr1*^−/−^ mice showed any anhedonia symptoms as measured by sucrose preference prior or after the inescapable shock stress suggesting that *Esr1* is not substantially involved in the development of these behavioral responses. These conclusions are also in agreement with our finding that both male and female *Esr1*^−/−^ mice do not manifest any differences in the FST compared with their wild-type controls. It has been recently reported that ERα in the nucleus accumbens drives a pro-resilient phenotype in both male and female mice ([@B35]). This is in apparent contrast with our findings demonstrating that lack of *Esr1*^−/−^ does not induce susceptibility to develop learned helplessness or result in changes in sucrose preference following stress in either sex. It may be that while increased ERa driven transcription mediates resilience, lack of the gene does not modulate susceptibility.

Although we demonstrated differential effects of both estrogen receptors in male and female mice in response to stress, we did not observe any effects of genetic deletion of estrogen receptors in anxiety-related tests. In line with our findings, Krezel et al. ([@B36]) demonstrated that both male and female *Esr1*^−/−^ mice had similar thigmotaxis and spent similar time in open arms of the EPM compared with wild-type mice. While, our findings in male *Esr2*^−/−^ mice are also in agreement with other reports ([@B36], [@B37]), their finding that female *Esr2*^−/−^ mice have higher anxiety-like behaviors compared with wild-type mice, as measured by the EPM and OFT, are in contrast with the results presented here. In line with our findings, other reports demonstrated that female *Esr2*^−/−^ have similar performance on anxiety behavioral tests as wild-type mice ([@B23], [@B38]). Interestingly, Walf et al. ([@B38]) also demonstrated that female wild-type as well as in *Esr2*^−/−^ mice during proestrous compared with diestrous had higher open field-central entries, which was interpreted as an anxiolytic effect. Therefore, future studies should address this limitation and further investigate the effects of the estrous cycle and estrogen receptors in anxiety-like behaviors.

Moreover, another limitation of the current study is the use of heterozygous mice for *Esr2* instead of wild-type as controls. This might be particularly important when negative results are obtained, such as for the anxiety-related behaviors, since heterozygous mice might have different phenotypes than wild-types. However, it was previously shown that *Esr2*^+/−^ behave in a similar manner as wild-type mice in the elevated plus-mice ([@B39]), a test assessing anxiety-like behaviors. Considering this, and the fact that our findings are also in agreement with other studies ([@B20], [@B36], [@B37], [@B40]) provides confidence to our results. However, for this reason the negative results comparing *Esr2*^+/−^ to *Esr2*^−/−^ should be interpreted cautiously as a full wild-type control was not included in the experimental design. In addition, since we are using conventional knockout mice, the absence of differences in these behaviors could be due to compensatory mechanisms.

Sex differences have been reported in patients with major depression, with male, but not female, patients demonstrating decreased PPI compared with healthy controls ([@B41], [@B42]). In order to test if estrogen receptors might be implicated in these sex differences, we assessed male and female *Esr1* and *Esr2* knockout mice in the PPI paradigm. Although we observed no significant difference with the male *Esr1*^−/−^ and *Esr2*^−/−^ mice, deletion of estrogen receptors in female mice exerted differential effects. Specifically, contingency analysis demonstrated a near significant decrease in % PPI in *Esr1*^−/−^ compared with *Esr1*^+/+^. This may be related to the finding that a decrease in % PPI is observed in rodents following ovariectomy, an effect that is normalized with estradiol replacement ([@B43], [@B44]); thus, considering our results we postulate that this decrease is attributed to the actions of estradiol through ERα. In contrast with the effects of *Esr1* deletion, female *Esr2*^−/−^ mice manifested higher PPI than their littermate controls suggesting an enhanced sensorimotor gating response. In combination with our findings that deletion of *Esr2* gene in female mice results in decreased escape failures, and the literature demonstrating stress-induced decreases in PPI ([@B45]--[@B47]), these results suggest that deletion of *Esr2* gene in females might result in stress resilience. Enhanced PPI in this case might be also associated with an improved ability of these mice to deal with information processing. Moreover, considering the literature supporting a protective effect of estradiol in women with schizophrenia \[see ([@B48])\], our findings cannot preclude that the differential regulation of PPI response in *Esr1* and *Esr2* knockout female mice might have a functional relevance to schizophrenia. However, further investigation is warranted for better understanding this finding and the possible implications of estrogen receptors in stress resilience and/or schizophrenia.

Furthermore, we observed that male *Esr1*^−/−^ mice showed attenuated response to amphetamine, as measured by hyperlocomotion, compared with *Esr1*^+/−^ and *Esr1*^+/+^, suggesting a possible interaction between *Esr1*^−/−^ and the dopaminergic signaling. The possible interaction between *Esr1* and the dopaminergic system is also supported by the findings that male mice lacking *Esr1* have decreased tyrosine hydroxylase (TH) mRNA and protein levels in the midbrain ([@B49]), which might also explain our findings that male *Esr1*^−/−^ mice manifest attenuated response to amphetamine-induced hyperlocomotion compared with WT mice. A possible interaction between these two systems is further supported by our findings in female mice; however, in this instance lack of *Esr1* in females enhanced the amphetamine-induced hyperlocomotion compared with controls. A decrease in TH mRNA and protein levels in the midbrain was also observed in female mice lacking *Esr1*^−/−^ ([@B49]). These differences in the amphetamine-induced locomotion in *Esr1*^−/−^ mice could be related to this finding, or could be influenced by differences in their hormonal status compared with WT mice. Both male and female *Esr1*^−/−^ mice display highly atrophied reproductive organs and are infertile ([@B50]--[@B53]) and female *Esr1*^−/−^ mice are anovulatory and acyclic ([@B54], [@B55]). Considering that gonadal hormones can affect dopamine response \[see ([@B56]--[@B58])\], the difference in the hormonal status of these mice could contribute to the observed differences in amphetamine-induced hyperlocomotion. An enhancement of amphetamine-induced hyperlocomotion was also observed in female *Esr2* knockout mice compared with their respective controls, whereas no difference was observed in male *Esr2*^−/−^ mice. Female *Esr2*^−/−^ have been reported to have similar levels of TH immunoreactive cells in the midbrain compared to WT mice ([@B59]), though this does not preclude differences in dopamine neuron activity or release. Interestingly, ERα and ERβ agonists have been shown to reverse the amphetamine-induced disruption of PPI ([@B60]), which further supports a role of these receptors in modulating response to amphetamine. In addition, estradiol is known to modulate several dopamine-related behaviors such as sexual motivation ([@B61]), as well as to increase the rewarding effects of *d-*amphetamine ([@B62], [@B63]); however, the exact role of estrogen receptors needs to be further investigated.

Overall, we demonstrate that deletion of either *Esr1* or *Esr2* differentially affects the development of stress-related responses as well as psychomotor responses in male and female mice. Specifically, deletion of *Esr2* in male mice led to increased susceptibility for the development of stress-related maladaptive behaviors, whereas deletion of *Esr2* in female mice resulted in resilience against the development of such behaviors. Also the amphetamine locomotor response was attenuated in male *Esr1*^−/−^ mice, while female *Esr1*^−/−^ and *Esr2*^−/−^ showed enhanced response. The present findings suggest that differential manipulation of *Esr1* and *Esr2* in males and females might have potential applications for the treatment of mood disorders.
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